ArticlePloS one2013
Light-emitting channelrhodopsins for combined optogenetic and chemical-genetic control of neurons.
Article in PloS one, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 57 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
57 citing papers in PubMed, 90 citations in OpenAlex.
- A bioluminescent activity dependent platform, BLADe, for converting intracellular activity to photoreceptor activation.Scientific reports · 2026Article
- Labeling and imaging of neurons with a genetically encoded autonomous bioluminescence system.Scientific reports · 2026Article
- Magneto-Photonic Gene Circuit for Minimally Invasive Control of Gene Expression in Mammalian Cells.ACS omega · 2026Article
- Magneto-Photonic Gene Circuit for Minimally Invasive Control of Gene Expression in Mammalian Cells.bioRxiv : the preprint server for biology · 2025Article
- Control of Synaptic Communication through Molecularly Engineered Bioluminescence Light Emission and Sensing.bioRxiv : the preprint server for biology · 2025Article
- A Bioluminescent Activity Dependent (BLADe) Platform for Converting Intracellular Activity to Photoreceptor Activation.bioRxiv : the preprint server for biology · 2025Article
- Presymptomatic targeted circuit manipulation for ameliorating Huntington's disease pathogenesis.iScience · 2025Article
- Principles and Design of Molecular Tools for Sensing and Perturbing Cell Surface Receptor Activity.Chemical reviews · 2025Review
- Bioluminescent Systems for Theranostic Applications.International journal of molecular sciences · 2024Review
- Efficient opto- and chemogenetic control in a single molecule driven by FRET-modified bioluminescence.Neurophotonics · 2024Article
- Recent advances in bioluminescent probes for neurobiology.Neurophotonics · 2024Article
- BioLuminescent OptoGenetics in the choroid plexus: integrated opto- and chemogenetic controlNeurophotonics · 2024Article
- Bioluminescence as a functional tool for visualizing and controlling neuronal activityNeurophotonics · 2024Article
- Engineering luminopsins with improved coupling efficiencies.Neurophotonics · 2024Article
- An Innovative Mitochondrial-targeted Gene Therapy for Cancer Treatment.bioRxiv : the preprint server for biology · 2024Article
- Engineering luminopsins with improved coupling efficiencies.bioRxiv : the preprint server for biology · 2023Article
- Coelenterazine-Type Bioluminescence-Induced Optical Probes for Sensing and Controlling Biological Processes.International journal of molecular sciences · 2023Review
- Improved Locomotor Recovery in a Rat Model of Spinal Cord Injury by BioLuminescent-OptoGenetic (BL-OG) Stimulation with an Enhanced Luminopsin.International journal of molecular sciences · 2022Article
- Microliter Scale Synthesis of Luciferase-Encapsulated Polymersomes as Artificial Organelles for Optogenetic Modulation of Cardiomyocyte Beating.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2022Article
- Experimental approaches for manipulating choroid plexus epithelial cells.Fluids and barriers of the CNS · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 3 countries.
Funding
Abstract
Manipulation of neuronal activity through genetically targeted actuator molecules is a powerful approach for studying information flow in the brain. In these approaches the genetically targeted component, a receptor or a channel, is activated either by a small molecule (chemical genetics) or by light from a physical source (optogenetics). We developed a hybrid technology that allows control of the same neurons by both optogenetic and chemical genetic means. The approach is based on engineered chimeric fusions of a light-generating protein (luciferase) to a light-activated ion channel (channelrhodopsin). Ionic currents then can be activated by bioluminescence upon activation of luciferase by its substrate, coelenterazine (CTZ), as well as by external light. In cell lines, expression of the fusion of Gaussia luciferase to Channelrhodopsin-2 yielded photocurrents in response to CTZ. Larger photocurrents were produced by fusing the luciferase to Volvox Channelrhodopsin-1. This version allowed chemical modulation of neuronal activity when expressed in cultured neurons: CTZ treatment shifted neuronal responses to injected currents and sensitized neurons to fire action potentials in response to subthreshold synaptic inputs. These luminescent channelrhodopsins--or luminopsins--preserve the advantages of light-activated ion channels, while extending their capabilities. Our proof-of-principle results suggest that this novel class of tools can be improved and extended in numerous ways.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.